Neuroblastoma Drugs Market 2025 | Industry Developments, Future Growth, Share & Industry Insights | Eli Lilly and Company, Marsala Biotech, Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG

Neuroblastoma Drugs Market is expected to grow at a CAGR of 7% during the forecast period 2024-2031

DataM Intelligence unveils its latest report on the "Neuroblastoma Drugs Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/neuroblastoma-drugs-market?sg

List of Top Key Player: Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc, MacroGenics, Bristol-Myers Squibb Company, Eli Lilly and Company, Marsala Biotech Inc, Pfizer Inc.

United States - Industry Developments:

✅ FDA Approval of IFINWIL® (eflornithine): On July 8, 2025, Swissmedic approved IFINWIL® (eflornithine) for children diagnosed with high-risk neuroblastoma (HRNB).

✅ SERB Pharmaceuticals Acquires Y-mAbs Therapeutics: On August 6, 2025, SERB Pharmaceuticals acquired Y-mAbs Therapeutics in a $412 million deal, including the neuroblastoma drug Danyelza.

Japan - Industry Developments:

✅ Orphan Drug Designation for Tazemetostat: On August 29, 2025, the Ministry of Health, Labour and Welfare granted orphan drug designation to tazemetostat for unresectable INI1-negative epithelioid sarcoma.

✅ Drug Lag in Pediatric Neuroblastoma Treatments: As of 2025, Japan has not granted regulatory approval for isotretinoin, an established standard drug for high-risk neuroblastoma, despite its use since the 2000s.

South Korea - Industry Developments:

✅ Qarziba (dinutuximab beta) Insurance Coverage: On August 25, 2025, Korea's MFDS facilitated insurance coverage for Qarziba (dinutuximab beta) within six months of approval, streamlining patient access.

✅ Domestic Production of Actinium-225: By mid-2025, South Korea began domestic production of actinium-225, enhancing the development of radiopharmaceuticals for cancer treatment.

Europe - Industry Developments:

✅ EMA Marketing Authorization Application for IFINWIL®: On January 7, 2025, a marketing authorization application was submitted to the European Medicines Agency for IFINWIL® (eflornithine) in high-risk neuroblastoma.

✅ EMA CHMP Meeting Recommendations: On July 25, 2025, the EMA's human medicines committee recommended granting marketing authorization for 13 medicines, including treatments for various cancers.

Forecast Projection:

The Global Neuroblastoma Drugs Market is poised for significant growth between 2025 and 2032. In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period. Companies leveraging these trends are well-positioned to capture emerging opportunities and maximize revenue potential.

Market Intelligence Research Process:

The Neuroblastoma Drugs Market research report by DataM Intelligence combines primary and secondary data to deliver deep, actionable insights. It examines the full spectrum of factors shaping the industry, from government regulations and market conditions to competitive dynamics, historical trends, technological breakthroughs, upcoming innovations, and potential challenges. This comprehensive analysis not only highlights growth prospects but also identifies barriers, equipping businesses to navigate market volatility and capitalize on emerging opportunities.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=neuroblastoma-drugs-market?sg

Key Segmentation:

By Drug Type (Dinutuximab, Cisplatin, Doxorubicin, Vincristine, Etoposide, Others)

By Distribution Channel (Hospital Pharmacies, Clinics, Cancer research institutes, Others)

By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa)

Global Growth Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1 - Market Overview: Kickstarts the report with a comprehensive snapshot of the Neuroblastoma Drugs Market, summarizing key segments by region, product type, and application. Highlights include market size, segment growth potential, and short- & long-term industry outlook.

Chapter 2 - Emerging Trends: Uncovers the game-changing trends and high-impact innovations shaping the future of the industry.

Chapter 3 - Competitive Landscape: Offers a deep dive into market competition, detailing revenue shares, strategic initiatives, and recent mergers & acquisitions.

Chapter 4 - Top Player Profiles: Features detailed company profiles, covering revenue, profit margins, product lines, and major milestones for leading market players.

Chapters 5 & 6 - Regional & Country Analysis: Breaks down revenue performance across global regions, providing insights on market sizes, opportunities, and growth prospects worldwide.

Chapter 7 - Segmentation Analysis: Explores market segmentation by type, revealing high-potential categories and guiding businesses towards lucrative areas.

Chapter 8 - Application Insights: Examines downstream markets and identifies promising sectors for expansion, showing how different applications are driving growth.

Chapter 9 - Supply Chain Mapping: Maps the entire industry supply chain, highlighting upstream and downstream activities for a holistic market perspective.

Chapter 10 - Key Takeaways: Concludes with critical insights and actionable strategies, equipping stakeholders to make informed decisions and stay ahead in the market.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/neuroblastoma-drugs-market?sg

FAQ's

Q1: How fast is the Neuroblastoma Drugs Market expected to grow in the coming years?

A: The market is forecast to expand at a robust CAGR of 7% between 2024-2031, signaling strong global growth and investment potential.

Q2: Which regions are dominating the Neuroblastoma Drugs Market and which are fastest-growing?

A: North America region holds the largest market share global Neuroblastoma drugs market.

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.